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Abstract
Introduction: The purpose of the present study was to investigate the frequency of the PTPN22 +1858 C/T single
nucleotide polymorphism (SNP) (rs 2476601), previously shown to be associated with several autoimmune diseases,
in patients with psoriatic arthritis (PsA) in comparison with population based controls.
Methods: A total of 291 patients (145 male/146 female, mean age (± S.D.) 52.2 (± 13.1) years) with PsA were
examined clinically, by standard laboratory tests and their DNA was genotyped for the SNP rs2476601 (PTPN22
+1858 C/T). Allelic frequencies were determined and compared with 725 controls.
Results: Carriage of the risk allele, PTPN22+1858T, showed a significant association with patients with PsA
compared with controls (c
2 = 6.56, P = 0.010, odds ratio (OR) 1.49; 95% confidence interval (CI) 1.10 to 2.02).
A significantly higher proportion of carriers of the risk allele (T) had significantly more deformed joints (n ± SEM)
(5.9 ± 1.2 vs 2.8 ± 0.5; P = 0.005).
Conclusions: In this study the +1858T allele of the PTPN22 gene, known to be associated with several
autoimmune diseases, was associated with PsA. The finding of significantly more joints with deformities among
carriers of the T variant could indicate a more aggressive phenotype of disease.
Introduction
Psoriatic arthritis (PsA) is a heterogeneous inflammatory
arthritis associated with psoriasis. The disease severity
not only varies between patients but also within an indi-
vidual patient over time. The disease expression can vary
from a mild mono-oligoarthritis to severe erosive polyar-
thritis comparable with rheumatoid arthritis (RA) [1]. In
contrast to RA, manifestations such as dactylitis and
enthesitis are common in patients with PsA, as is the
case in patients suffering other diseases within the sero-
negative spondylarthropathy group [2,3]. Also, in contrast
with RA, most individuals with PsA are sero-negative for
rheumatoid factor (RF) and anti-citrullinated protein/
peptide antibodies (ACPA) [4,5].
As with many other autoimmune diseases a number of
genes have been suggested to be associated with PsA
[6,7]. Epidemiological data implicate a strong genetic
basis for PsA [6,8]. Familial aggregation with an esti-
mated recurrence risk ratio in first degree relatives (l1)
of 55 in different studies compared with 5 to 10 for
patients with cutaneous psoriasis, has been reported in
different studies [6,8]. Previous genetic studies have
shown multiple polymorphisms within the MHC region
on chromosome 6p to be associated with PsA together
with a number of candidate genes outside this region
being suggested [6,7].
The protein tyrosine phosphatase non-receptor
22 (PTPN22) gene, located on chromosome 1p13, codes
for a protein, Lyp, thought to function as a negative regu-
lator of T-cells [9] although a role in B-cell signaling has
also been recently suggested [10]. The single nucleotide
polymorphism (SNP) rs2476601 (+1858C/T), located in
exon 14 of the PTPN22 gene, has previously been found
associated with several autoimmune diseases, for example,
diabetes type-I [11] and RA, with a stronger association
with ACPA sero-positive RA [12,13]. Previous studies
investigating an association between PTPN22 +1858C/T
and susceptibility to PsA have shown conflicting results
[14-16].
The aim of the present study was to ascertain whether
the PTPN22 +1858C/T polymorphism was associated
with susceptibility to, or severity of, disease in well-
characterized patients with PsA from northern Sweden.
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Patients
This case-control study comprised 291 consecutively
included patients with PsA (145 male/146 female, with a
mean age (± S.D.) of 52.2 (± 13.1) years) and 725 controls
(265 male/460 female, mean age (± S.D.) 55.6 (± 12.4).
All patients and controls were from the same geographic
area of northern Sweden and all controls were randomly
selected from the Medical Biobank of Northern Sweden.
PsA was diagnosed when a patient presented with an
actual psoriasis, or a history of psoriasis, of the skin com-
bined with inflammatory arthropathy defined as periph-
eral arthritis (out of 66/68 joint) of more than six weeks
duration and/or radiologically assessed axial involvement
based on radiological findings in the sacroiliac joints
according to the New York criteria (≥2) [17] and/or syn-
desmophytes, ligamentous ossification, vertebral squaring
and shining corners of the spine [18]. Dactylitis was
defined as painful swelling and inflammation of a finger
or a toe and, deformed joints were defined as radiological
erosions and/or irreversible deformations (for example,
ankylosis, subluxation and/or loss of function or reduced
mobility). Patients were examined clinically, by laboratory
based analysis and, if needed for proper classification of
diagnosis, radiologically, and. subsequently, classified
according to the criteria of Moll and Wright and of the
CASPAR study group [1,5]. The local ethics committee
at Umeå University, Sweden, approved the study, and all
patients and controls gave their written informed con-
sent. Table 1 shows the demographic data and phenotype
of the patients at the time of the study.
Genotyping
DNA from the patients and controls was extracted from
ethylenediamine tetraacetic acid-treated whole blood
using a standard technique and genotyped for the SNP
rs2476601 (PTPN22 +1865C/T) allele by the TaqMan
®
assay using an ABI PRISM 7900HT Sequence Detection
System and the SDS 2.1 software (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s
instructions.
Laboratory analysis
Blood samples were collected when the patients were
assessed clinically. The erythrocyte sedimentation rate
(ESR; mm/h) and C-reactive protein (CRP; mg/L) were
analyzed using standard protocols by the authorized
chemical laboratory at the University Hospital of Umeå.
Rheumatoid factor (RF) was measured using the ORG
522 M Rheumatoid Factor IgM ELISA kit (Orgentic
Diagnostika GmbH, Mainz, Germany) with a cut-off
value >20 IU/mL. The presence of anti-citrullinated pro-
tein/peptide antibodies (ACPA) was determined using
the DIASTAT Anti-CCP ELISA kit FCCP200 from
Axis-Shield Diagnostics Limited (Technology Park,
Dundee, Scotland, UK) and a cut off value >5 U/mL.
Statistics
Statistical calculations were performed using SPSS 16.0
(SPSS Inc., Chicago, IL, USA). The Chi-square test was
used for testing categorical data between groups. Odds
ratio (OR) was calculated with 95% confidence interval
(CI). All P-values refer to a two-sided test and a P-value
≤0.05 was considered statistically significant. For multi-
variate analysis, logistic regression analysis was used.
Power calculation was performed using EpiInfo. To esti-
mate the number of patients and controls needed, fre-
quency data from a previous study were used [16].
Results
The genotype and allele distribution of the PTPN22
+1858C/T SNP among patients and controls were in
agreement with the Hardy-Weinberg equilibrium. Using
the minor allele frequency of 0.085, which was reported
for the Toronto population in an article by Butt et al.
[16], the present study had more than 80% power to
detect an effect size of 2.00 and a power near 70% to
detect an effect size of 1.8 and approximately 35%
power to detect an effect size of 1.5.
Carriage of the PTPN22 +1858T variant (CT + TT)
was significantly increased in patients with PsA com-
pared with controls (c
2 =6 . 5 6 ,P = 0.010, OR 1.49 (95%
CI 1.10 to 2.02)) (Table 2). Allelic frequency of risk
Table 1 Demographic data and phenotype of patients at
the time of the study
Age (years) 52.2 ± 13.1
PsA duration (years) 15.2 ± 11.7
Tender joints (mean ± SEM) 6.6 ± 0.5
Swollen joint (mean ± SEM) 4.4 ± 0.3
Duration of skin disease (years) 25.3 ± 14.8
Duration of joint disease (years) 14.3 ± 11.4
ESR mm/h 16.2 ± 15.7
CRP mg/L 10.5 ± 8.1
Arthritic joints (mean ± SEM) 3.0 ± 0.2
Deformed joint (mean ± SEM) 3.8 ± 0.5
Rheumatoid factor positive 34 (11.9%)
Anti-citrullinated protein/peptide antibodies positive 21 (7.3%)
Nail involvement 121 (42.6%)
DIP-joint involvement 93 (33.2%)
Dactylitis “ever” 64 (23.4%)
Fulfilling CASPAR 247 (92.9%)
Mono-/oligoarthritis 117 (41.3%)
Polyarthritis 135 (47.7%)
Axial involvement 60 (20.8%)
Data presented by mean ± SD or n (%) when appropriate, unless stated
otherwise.
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patients, that is, 0.160 versus 0.119. The association was
further increased when RF sero-positive patients were
excluded (c
2 = 8.56, P = 0.003, OR 1.61 (95% CI 1.17 to
2.21)) as well as when ACPA sero-positive patients were
excluded (c
2 = 6.63, P = 0.010, OR 1.51 (95% CI 1.10 to
2.07)). Only 6 patients (2.1%) and 10 controls (1.3%)
were homozygous for the T-allele (c
2 = 0.62, P = 0.430).
This subgroup is thus too small to allow appropriate
statistical calculations.
When analyzing the separate disease phenotypes, a sig-
nificantly higher proportion of carriers of the risk allele,
T, had, at some point, been diagnosed with dactylitis
(c
2 = 10.56, P = 0.001, OR 2.58 (95% CI 1.44 to 4.62)).
Furthermore, they had significantly more deformed joints
at examination compared with non-carriers (mean num-
ber of joints ± SEM; 5.9 ± 1.2 vs 2.8 ± 0.5; P =0 . 0 0 5 ) ,
and this association remained significant after multiple
logistic regression analysis (P = 0.017). There was no
association between dactylitis and deformed joints and,
no other significant associations between the carriage of
the risk allele, T, and other examined disease phenotypes,
for example, number of swollen or tender joints at exam-
ination, axial disease, level of ESR or CRP, nail psoriasis
or distal interphalangeal (DIP)-joint involvement (data
not shown). Furthermore, there was no significant differ-
ence in the allelic distribution in patients with mono-
oligoarthritic disease compared with those having a
polyarthritic disease expression (data not shown).
There were no significant differences in genotyped
allelic frequencies between males and females, either for
the patients or the controls (data not shown).
Discussion
In this study of clinically and laboratory well character-
ized patients with PsA, the +1858T allele of the PTPN22
gene, previously shown to be associated with several
autoimmune diseases, was found to be associated with a
diagnosis of PsA.
Previous association studies regarding PTPN22 +1858C/
T polymorphism and PsA have produced conflicting
results. In a study by Hinks et al., no association was
found between PsA and PTPN22 +1858C/T in a patient
population from the United Kingdom [14]. Likewise, no
association was found between PsA and PTPN22 +1858C/
T in a German cohort of 375 patients with PsA when the
patient group was considered as a whole; however, a sig-
nificantly higher proportion of males carried the risk allele
[15]. In a study of two Canadian populations, one from
Toronto and one from Newfoundland, an association
between PTPN22 +1858C/T and PsA was only found in
the Toronto population [16]. In that study, the T-allele
frequency of the Toronto population was significantly
increased in PsA patients, 0.138 compared with 0.085 in
controls. Thus, our results are consistent with those
reported for the Toronto population by Butt et al., but are
in contrast with the others cited. This could indicate that
association with PTPN22 exists in specific populations, as
to date exemplified by the Toronto population by Butt
et al.a n dt h ep o p u l a t i o nf r o mn o r t h e r nS w e d e ni nt h e
present study. Alternatively, as suggested by the Canadian
authors, a false positive association is, of course, possible
due to population stratification. It is also possible that
further studies with increased sample sizes would detect
significant associations among other populations. The
association with the male gender observed within the
German cohort [15] was not confirmed by this study in
which no differences in allelic frequencies between males
and females could be detected. In all three studies cited
here the distribution between patients and controls are
different compared with the present study. The patient:
control ratio in our study is 291:725, in the UK cohort
455:595 [14], in the German patient group 375:299 [15], in
the Newfoundland cohort 238:149 and in the Toronto
cohort 207:199 [16]. These differences make direct com-
parison between the various studies difficult. However, fol-
lowing our calculations, the only study with more power
than the present study is that based on the UK cohort; in
all of the other studies the power value is at the same level
or lower than in the present study. Since the allelic fre-
quency of PTPN22+1858T varies considerably among dif-
ferent populations, for example, within Caucasian
populations in Europe it varies from 2 to 3% in the south
of Europe to >10% in Scandinavian countries [19] it is
important to incorporate an appropriately large group of
controls with a homogeneous origin. Our control group
Table 2 Frequency distribution of PTPN22 +1858 C/T polymorphism in psoriatic arthritis patients and controls
Genotype Patients (n = 291)
n (%)
Controls (n = 725)
n (%)
c
2 P-value OR 95% CI
CC 204 (70.1) 563 (77.7) 6.40 0.011 0.67 0.49 to 0.93
CT 81 (27.8) 152 (21.0) 5.54 0.019 1.45 1.05 to 2.01
TT 6 (2.1) 10 (1.3) 0.62 0.430 1.51 0.48 to 4.54
CT+TT 87 (29.9) 162 (22.3) 6.56 0.010 1.49 1.10 to 2.02
T allele 93 (16.0) 172 (11.9) 6.21 0.013 1.41 1.07 to 1.87
CI, confidence interval; OR, odds ratio.
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lished studies and was selected from the same geographic
area as the patients. A possible explanation for the positive
association between PTPN22 and PsA could have been
that misdiagnosed patients were included in the study.
Anyhow, when patients with positive RF and ACPA were
excluded, the OR increased, indicating that the result was
not caused by misdiagnosed patients.
Interestingly, our study revealed that carriers of the
risk allele, PTPN22 +1858 T, had significantly more
joints with deformities. There was no association found
with a polyarthritic disease pattern, thus the results of
this study could indicate that carriage of the risk allele,
T ,i sar i s kf a c t o rf o ram o r ea g g r e s s i v ef o r mo fP s A ,
although not with a disease pattern having similarities
to RA.
A limitation of this study is that the number of
patients studied does not allow proper stratification of
the data, for example, the number of RF and ACPA
sero-positive subjects is too small to allow appropriate
calculation. Therefore, it was not possible to evaluate
properly any likely association in these sub-groups.
Conclusions
In conclusion, this study shows that the +1858T allele in
the PTPN22 gene, previously shown to be associated
with several autoimmune diseases, is also associated
with PsA in patients from northern Sweden, a result
that is consistent with previous data regarding a popula-
tion from Toronto. Carriers of the T-allele also had sig-
n i f i c a n t l ym o r ej o i n t sw i t hd eformities compared with
non-carriers of the T-allele, possibly indicating a more
aggressive phenotype of disease.
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